Cancer Research The Future of Cancer Research: Science and Patient Impact  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 55, 840-846, February 15, 1995]
© 1995 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hooijberg, E.
Right arrow Articles by Hekman, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hooijberg, E.
Right arrow Articles by Hekman, A.

Enhanced Antitumor Effects of CD20 over CD19 Monoclonal Antibodies in a Nude Mouse Xenograft Model1

Erik Hooijberg, Paul C. M. van den Berk, Johan J. Sein, John Wijdenes, Augustinus A. M. Hart, René W. de Boer, Cornelis J. M. Melief and Annemarie Hekman2

Department of Immunology [E. H., P. C. M. v. d. B., J. J. S., R. W. d. B. A. H.] and Department of Radiotherapy [A. A. M. H.], The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Innotherapie, BP 1985, Besançon, F25020 Cedex, France [J. W.]; and Academic Hospital Leiden, POB 9600, 2300 RC Leiden, the Netherlands [C. J. M. M.]

We used a nude mouse xenograft tumor model to compare the efficacy of unconjugated CD19 and CD20 mAbs (IgG2a subclass) in mediating antilymphoma effects. Treatment with the CD20 mAbs NKI-B20 and BCA-B20 resulted in a drastic decrease in tumor take rate (P < 0.0001) in comparison to controls, whereas the CD19 mAb CLB-CD19 was ineffective. Tumor growth rates were reduced by both CD19 and CD20 (P < 0.0001). The decrease in growth rate induced by NKI-B20 or BCA-B20 was larger than that induced by CLB-CD19 (P = 0.0022). In vitro experiments showed that NKI-B20 or BCA-B20 are more powerful than CLB-CD19 in mediating lysis by interleukin 2-activated natural killer cells. No difference was observed between different isotypes (IgG1, IgG2a, IgG2b) of the switch variants of NKI-B20 or CLB-CD19. A positive correlation between antigen density and the sensitivity to antibody-dependent cellular cytotoxicity was demonstrated with human lymphoblastoid B cells, JY, transfected with cDNA encoding the human CD19 antigen that expressed high levels of this antigen. These cells are more efficiently killed by natural killer cells when coated with CLB-CD19 mAbs than JY wild-type cells that express 1 log lower levels of the CD19 antigen. Antibody-dependent cellular cytotoxicity experiments with thioglycolate-activated macrophages show a more complex relationship between antigen density, isotype of the mAb, and cytotoxicity. BCA-B20 (IgG2a) and CLB-CD19 (IgG2a) and all isotypes of NKI-B20 mediated strong cytotoxicity, whereas CLB-CD19 isotypes IgG1 and IgG2b were associated with limited cytotoxicity. Proliferation of Daudi cells was inhibited with high concentrations of all isotypes of CLB-CD19, but not with any of the CD20 mAbs. To our knowledge this is the first report showing that the antitumor effects in vivo of unconjugated CD20 mAbs are far superior to those of CD19 mAbs.

1 Supported by Grant NKI 89-06 from the Koningin Wilhelmina Fonds (The Dutch Cancer Society) to E. H. and P. C. M. v. d. B.

2 To whom correspondence should be addressed, at Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.

Received 8/ 3/94. Accepted 12/13/94.




This article has been cited by other articles:


Home page
J. Immunol.Home page
A. J. Stel, B.-J. Kroesen, S. Jacobs, H. Groen, L. F. M. H. de Leij, H. C. Kluin-Nelemans, and S. Withoff
The Role of B Cell-Mediated T Cell Costimulation in the Efficacy of the T Cell Retargeting Bispecific Antibody BIS20x3
J. Immunol., November 15, 2004; 173(10): 6009 - 6016.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Tiroch, B. Stockmeyer, C. Frank, and T. Valerius
Intracellular Domains of Target Antigens Influence Their Capacity to Trigger Antibody-Dependent Cell-Mediated Cytotoxicity
J. Immunol., April 1, 2002; 168(7): 3275 - 3282.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Hooijberg, J. J. Ruizendaal, P. J. F. Snijders, E. W. M. Kueter, J. M. M. Walboomers, and H. Spits
Immortalization of Human CD8+ T Cell Clones by Ectopic Expression of Telomerase Reverse Transcriptase
J. Immunol., October 15, 2000; 165(8): 4239 - 4245.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Hooijberg, A. Q. Bakker, J. J. Ruizendaal, and H. Spits
NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells
Blood, July 15, 2000; 96(2): 459 - 466.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M.-A. Ghetie, E. M. Podar, A. Ilgen, B. E. Gordon, J. W. Uhr, and E. S. Vitetta
Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells
PNAS, July 8, 1997; 94(14): 7509 - 7514.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1995 by the American Association for Cancer Research.